EXCLUSIVE: SAB Biotherapeutics' Influenza Immunotherapy Shows Safety, Efficacy In Early-Stage Trials

SAB Biotherapeutics Inc SABS has announced the presentation of safety and efficacy data from Phase 1 and 2a trials of its influenza immunotherapy, SAB-176.

It has recently received FDA Breakthrough Therapy and Fast Track Designations.

What Happened: The data was presented at the AVG conference hosted by the International Society for Influenza and Other Respiratory Virus Diseases (ISIRV).

SAB-176 is a fully human, broadly neutralizing immunoglobulin antibody therapeutic designed to prevent or reduce severe outcomes of Type A and Type B influenza infection in patients at high risk for severe complications, including in patients who are immunocompromised. 

Results: In a Phase 2a challenge clinical trial, healthy adults (n=60) were given a 25 mg/kg dose of SAB-176 or placebo after being inoculated with H1N1. 

Results showed that SAB-176 was safe, well-tolerated, and demonstrated a significant reduction in viral load compared to placebo and symptom reduction.

A preclinical study in mice indicated that the combination of low doses of SAB-176 and oseltamivir (Tamiflu) protected against a lethal dose of H1N1 comparable to a high dose of oseltamivir alone.

Tamiflu is an antiviral medication from Genentech, a Roche Holdings AG RHHBY company.

Price Action: SABS shares closed at $0.87 on Wednesday.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareTop StoriesMarket-Moving ExclusivesExclusivesGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!